Assessing the diagnostic value of plasma-Free DNA in prostate cancer screening

ABSTRACT

Background: Prostate cancer is the second form of cancer among men worldwide. For early cancer detection, we should identify tumors in initial stages before the physical signs become visible. The present study aims to evaluate the diagnostic value of cell-free DNA [cfDNA], its comparison with prostate-specific antigen [PSA] level in prostate cancer screening and also in patients with localized prostate cancer, metastatic form, and benign prostatic hyperplasia [BPH]